Hostname: page-component-7479d7b7d-m9pkr Total loading time: 0 Render date: 2024-07-13T06:30:50.066Z Has data issue: false hasContentIssue false

Introduction and Overview of the Real World Management of Schizophrenia in the Comorbid Patient

Published online by Cambridge University Press:  07 November 2014

Extract

Simone is a 64-year-old African American female with a 25-year history of schizophrenia who had been hospitalized ∼10 times. Simone's last psychiatric hospitalization occurred 2 years prior to this presentation. She had been living in a supervised residence facility in a rural community with other patients and was generally adherent to her medications with encouragement by staff at her residence. Her psychotic symptoms had improved but had not disappeared. She continued to have persistent delusions that the Federal Bureau of Investigation was keeping her under surveillance because of information she supposedly had about national security. She continued to smoke 1 pack of cigarettes/day despite being told that she was developing chronic obstructive pulmonary disease. She stopped abusing alcohol, principally because of a lack of funds and lack of access to a liquor store. Simone was obese, with a body mass index (BMI) of 30 kg/m2. She was hypertensive, with a blood pressure of 140 over 95, and had mild abnormalities in her metabolic variables. She enjoyed fatty foods and never refused a meal.

Simone's case is not an unusual presentation for someone with schizophrenia. Psychiatric and somatic comorbidities in patients with schizophrenia are quite common. There is justifiable concern regarding long-term impact of treatments on metabolic variables, and metabolic comorbidities are often encountered.

Type
Research Article
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Sokal, J, Messias, E, Dickerson, FB et al. , Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis. 2004;192(6):421427.CrossRefGoogle ScholarPubMed
2.American Diabetes Association. The cardiometabolic risk initiative. Available at: http://professional.diabetes.org/ResourcesForProfessionals.aspx?cid=60379. Accessed April 21, 2010.Google Scholar
3.Citrome, L, Blonde, L, Damatarca, C. Metabolic issues in patients with severe mental illness. South Med J. 2005;98(7):714720.CrossRefGoogle ScholarPubMed
4.Flegal, KM, Carroll, MD, Ogden, CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):17231727.CrossRefGoogle ScholarPubMed
5.Ford, ES, Giles, WH, Dietz, WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356359.CrossRefGoogle ScholarPubMed
6.Holt, RIG, Bushe, C, Citrome, L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol. 2005;19(Suppl 6):5665.CrossRefGoogle ScholarPubMed
7.Lieberman, J, McEvoy, J, Stroup, S et al. , Comparative effectiveness of antipsychotic medications in patients with schizophrenia. Available at: www.catie.unc.edu/schizophrenia/synopsis.html. Accessed May 20, 2010.Google Scholar
8.Stroup, TS, McEvoy, JP, Swartz, MS et al. , The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29(1):1531.CrossRefGoogle ScholarPubMed
9.McEvoy, JP, Meyer, JM, Goff, DC et al. , Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):1932.CrossRefGoogle ScholarPubMed
10.Citrome, L, Jaffe, A, Levine, J, Martello, D. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals 1997–1994. Psychiatr Serv. 2006;57:11321139.CrossRefGoogle Scholar
11.Margolese, HC, Malchy, L, Negrete, JC, Tempier, R, Gill, K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res. 2004;67(2–3):157166.CrossRefGoogle ScholarPubMed
12.Drake, RE. Management of substance use disorder in schizophrenia patients: current guidelines. CNS Spectr. 2007;10(Suppl 17):2732.CrossRefGoogle Scholar